Insights & Resources

Get ahead of the curve by looking back at emerging trends in 2021 that are likely to impact health care valuation in 2022 and beyond.

Read about some of the impacts of increased hospital employment and accelerated retirements resulting in shortages of replacement physician investors.

The urgent care industry has been experiencing accelerated patient visit volume into 2021, continuing trends started in 2020.

Last week, the FFIEC issued a Joint Statement on Managing the LIBOR Transition, which highlighted risks associated with the discontinuation of LIBOR as well as supervisory expectations around this transition.

With the release of the “Pandora Papers,” there is renewed attention on transparency in corporate ownership.

Many business valuations begin with calculating a multiple of EBITDA (earnings before interest, taxes, depreciation, and amortization). In health care, however, valuators should deliberate just when and how to apply general valuation EBITDA transaction multiples for fair market value opinions.

Commentary from publicly traded Managed Care Organizations (MCOs) regarding their insurance spend expectations can be an excellent source of macroeconomic data for health care valuation professionals when projecting performance for provider entities.

Questions about the shelf life of a fair market value (FMV) opinion can arise when the parties seek certainty about compliance with government regulations or wish to maintain arrangements that are financially viable to all parties.

Professionals tasked with performing health care appraisals still face circumstantial challenges when performing their work fifteen months after the pandemic began. While a lot has changed, the basics of valuation have not.

On July 29, 2021 the Federal Deposit Insurance Corporation (FDIC) released Answers to Frequently Asked Questions about the Impact of London Interbank Offered Rate (LIBOR) Transitions on Regulatory Capital Instruments.